Enteric Disease Testing Market to Reach US$ 4,432.7 Million by 2027- CMI

Intestinal infections in enteric diseases can range from asymptomatic and mild to severe symptoms including abdominal cramps, vomiting, nausea and anorexia. Severe cases and symptoms under some cases may even lead to death as well due to heavy loss of fluids and essential nutrients from the body.

Statistics:

The global enteric disease testing market is estimated to account for US$ 3,732.7 Mn in terms of value by the end of 2020.

Global Enteric Disease Testing Market: Drivers

High incidence of typhoid fever is expected to propel growth of the global enteric disease testing market over the forecast period. For instance, according to the study, ‘The global burden of typhoid and paratyphoid fevers: a systematic analysis for the Global Burden of Disease Study 2017’, published in February 2019, globally, 14·3 million cases of typhoid and paratyphoid fevers occurred in 2017.

Global Enteric Disease Testing Market: Opportunities

R&D of new approaches is expected to offer lucrative growth opportunities for players in the global enteric disease testing market. For instance, in August 2020, researchers at Purdue University, U.S., reported development of a new 3D-printed capsule that allows sampling of gut bacteria for further analysis and possible identification of disease.

Global Enteric Disease Testing Market: Restraints

Low public heath expenditure, especially in emerging economies, is expected to hinder growth of the global enteric disease testing market.

Key Takeaways:

The global enteric disease testing market was valued at US$ 3,643.4 Mn in 2019 and is forecast to reach a value of US$ 4,432.7 Mn by 2027 at a CAGR of 2.5% between 2020 and 2027. High incidence of typhoid fever is expected to propel growth of the global enteric disease testing market over the forecast period.

Market Trends

R&D in enteric diseases is expected to propel growth of the global enteric disease testing market. For instance, in June 2020, researchers from University of Texas Southwestern Medical Center, U.S., reported that l-arginine sensing regulates virulence gene expression and disease progression in enteric pathogens.

Moreover, adoption of satellite observations in disease models is also expected to aid in growth of the market. Researchers can use Earth observing satellites to track when and where certain diseases will emerge and spread.

Global Enteric Disease Testing Market: Competitive Landscape

Major players operating in the global enteric disease testing market include, Alere, Inc., Becton Dickinson & Company, Biomerica, Inc., bioMerieux, Bio-Rad, Cepheid, Coris BioConcept, DiaSorin, Meridian Bioscience, Inc., Quest Diagnostics, and Trinity Biotech.

Global Enteric Disease Testing Market: Key Developments

Major players in the global enteric disease testing market are focused on approval and launch of new products to expand their product portfolio. For instance, in December 2018, Becton, Dickinson and Company received U.S. Food and Drug Administration (FDA) 510(k) clearance for its BD Max enteric viral panel, a molecular diagnostic test for the detection and differentiation of pathogens that cause viral gastroenteritis.

Segmentation

Scope of the report

Global Enteric Disease Testing Market, By Disease Type:
- E. coli Infection
- Salmonellosis
- Campylobacteriosis
- Rotavirus Infection
- Cryptosporidiosis
- Norovirus Infection
- Cholera
- C. difficile
- H. pylori
- Amebiasis
- Shigellosis
Global Enteric Disease Testing Market, By Region:
- North America
  - By Disease Type:
    - E. coli Infection
    - Salmonellosis
    - Campylobacteriosis
    - Rotavirus Infection
    - Cryptosporidiosis
    - Norovirus Infection
    - Cholera
    - C. difficile
    - H. pylori
    - Amebiasis
    - Shigellosis
  - By Country
    - U.S.
    - Canada
- Latin America
  - By Disease Type:
    - E. coli Infection
    - Salmonellosis
    - Campylobacteriosis
    - Rotavirus Infection
    - Cryptosporidiosis
    - Norovirus Infection
    - Cholera
    - C. difficile
    - H. pylori
    - Amebiasis
    - Shigellosis
  - By Country
    - Brazil
    - Mexico
    - Argentina
    - Rest of Latin America
- Europe
  - By Disease Type:
    - E. coli Infection
    - Salmonellosis
    - Campylobacteriosis
    - Rotavirus Infection
    - Cryptosporidiosis
    - Norovirus Infection
    - Cholera
    - C. difficile
    - H. pylori
    - Amebiasis
    - Shigellosis
  - By Country
    - U.K.
    - Germany
    - France
    - Spain
    - Italy
    - Russia
    - Rest of Europe
- Asia Pacific
  - By Disease Type:
    - E. coli Infection
    - Salmonellosis
    - Campylobacteriosis
    - Rotavirus Infection
    - Cryptosporidiosis
    - Norovirus Infection
    - Cholera
    - C. difficile
    - H. pylori
    - Amebiasis
    - Shigellosis
  - By Country
    - China
    - Japan
    - India
    - Australia
    - South Korea
    - ASEAN
    - Rest of Asia Pacific
- Middle East
  - By Disease Type:
    - E. coli Infection
    - Salmonellosis
    - Campylobacteriosis
    - Rotavirus Infection
    - Cryptosporidiosis
    - Norovirus Infection
    - Cholera
    - C. difficile
    - H. pylori
    - Amebiasis
    - Shigellosis
  - By Country
    - GCC Countries
    - Israel
    - Rest of Middle East
- Africa
  - By Disease Type:
    - E. coli Infection
    - Salmonellosis
    - Campylobacteriosis
    - Rotavirus Infection
    - Cryptosporidiosis
    - Norovirus Infection
    - Cholera
    - C. difficile
    - H. pylori
    - Amebiasis
    - Shigellosis
  - By Country
    - North Africa
    - Central Africa
    - South Africa
Company Profiles
- Alere, Inc. *
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Becton Dickinson & Company
- Biomerica, Inc.
- bioMerieux
- Bio-Rad
- Cepheid
- Coris BioConcept
- DiaSorin
- Meridian Bioscience, Inc.
- Quest Diagnostics
- Trinity Biotech
“*” marked represents similar segmentation in other categories in the respective section.